ArticleInternational archives of allergy and immunology2026
Long-Term Prophylaxis for Hereditary Angioedema: Real-World Treatment Patterns in Selected US Allergy Clinics.
Article in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary angioedema (HAE) is a rare genetic disorder which causes recurrent and unpredictable swelling attacks that pose high morbidity and risk of death. Long-term prophylactic (LTP) treatments are an important clinical management tool to reduce attack frequency. This study aims to assess real-world treatment patterns among US patients receiving LTP therapy.
methodsThe Patient Important Outcomes National Data Repository for Hereditary Angioedema (PIONEER) HAE registry contains structured and unstructured data for patients within the Consortium of Independent Immunology Clinics (CIIC). Eligibility criteria included diagnosis of HAE due to C1-inhibitor deficiency (HAE-C1NH), observation between April 2021 and March 2024 and record of a LTP therapy. Index therapy was defined as the earliest prophylactic therapy for which the patient had at least 180 days of medical history prior to initiation and 180 days of follow-up thereafter. Patients were observed for up to 3 years.
resultsThis study included 179 patients; most had HAE-C1INH Type 1 (86%) with median age 38 years (IQR: 25-53). Index therapy included kallikrein inhibitors (55%), C1-esterase inhibitors (37%), androgens (6%), and antifibrinolytic agents (2%); most often initiated in 2019 (21%). Eighty-three (46%, 83/179) discontinued index therapy, with a median 12 (IQR: 4.8-33) months to discontinuation. Discontinuations were most commonly due to lack of efficacy (29%, 22/76). Of those, 48/83 (58%) switched or restarted prophylactic therapy.
conclusionNearly half of patients discontinued their index LTP at some point during the observation period, primarily due to efficacy, administration, or dosing challenges. Advanced understanding of unmet treatment needs and other important factors in the HAE treatment landscape will require more robust and detailed data on real-world treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.